Physician profile
Harmeet Singh
NPI 1306866967
$2,432.85
in general payments reported to CMS, 2019-2025
21 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $170 · 2021: $495 · 2022: $258 · 2023: $217 · 2024: $367 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977 · Education: $48.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.39 |
| Education | $48.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $450.69 | 2019-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $426.76 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $242.78 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $219.18 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $174.84 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $158.29 | 2019-2025 | Jynarque |
| Baxter Healthcare | $139.50 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $90.25 | 2019-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $87.42 | 2021-2025 | Veltassa |
| Bard Peripheral Vascular, INC. | $79.46 | 2019 | |
| Novo Nordisk INC | $71.46 | 2024-2025 | Wegovy, Ozempic |
| Pfizer INC. | $60.06 | 2019 | |
| Travere Therapeutics, INC. | $47.43 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $34.90 | 2019 | |
| Horizon Therapeutics Plc | $33.23 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $26.90 | 2019-2020 | |
| Vantive US Healthcare LLC | $24.45 | 2025 | Renal - Chronic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.41 | 2025 | Jardiance |
| Genzyme Corporation | $18.17 | 2019 | |
| Amarin Pharma, INC. | $14.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harmeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.